April 16th 2024
A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab and Olaparib Combo Did Not Significantly Improve PFS and OS in mCRPC
September 12th 2022No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.
Read More
2-Year ADT Plus Radiotherapy Following Surgery Improves MFS in Prostate Cancer
September 12th 2022The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.
Read More
First-line Olaparib Triplet Improves Outcomes in mCRPC
September 11th 2022Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.
Read More
Enzalutamide/Abiraterone Acetate/Prednisolone Combo in mHSPC Not Recommended
September 11th 2022Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.
Read More
KEYNOTE-365 2-Year Update Shows Benefit of Pembrolizumab Plus Abiraterone in mCRPC
September 11th 2022An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.
Read More
Treating mCSPC with Anti-Androgen Therapy and Monitoring for Progression
August 17th 2022During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.
Read More
KEYNOTE-921 Trial of Pembrolizumab and Chemo Fails to Improve Survival in mCRPC
August 10th 2022The phase 3 KEYNOTE-921 trial did not meet its coprimary end points of overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Read More